Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2025)
40 slides from Optiscan Imaging's shareholder meeting presentation, Nov 14, 2025
Slide 1: The new standard in digital pathology and precision surgery
The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) Annual General Meeting 14 November 2025
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) on 14 November 2025 and approved for market release by the Board of Optiscan. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain
Slide 3: Chairman's Address
Chairman’s Address Mr Robert Cooke Non-Executive Chairman
Slide 4: Optiscan Board: Experienced Leadership
Optiscan Board: Experienced Leadership
Slide 5: Chairman's Address
Chairman’s Address Optiscan Imaging Limited (ASX: OIL) (the ‘Company’ or ‘Optiscan’) provides the following Chairman’s address which will be made to the Annual General Meeting of shareholders on 14 November 2025. Dear Fellow Shareholders, During FY25, Optiscan marked a major step forward in its evol
Slide 6: Chairman's Address
Chairman’s Address Operational Excellence and Manufacturing Performance Optiscan’s manufacturing and engineering performance remained strong, achieving 100% on-time fulfilment for the second consecutive year, with new probe and scanner designs validated and delivered for upcoming clinical programs.
Slide 7: Managing Director's Report
Managing Director’s Report Dr. Camile Farah CEO & Managing Director
Slide 8: Acknowledgement of Country
Acknowledgement of Country I begin today by acknowledging the Traditional Owners of the land on which we meet, the Wurundjeri and the Boon Wurrung people of the Kulin Nation, and pay my respects to their Elders past, present and emerging.
Slide 9: Pathology - the weakest link in modern medicine
Pathology - the weakest link in modern medicine • Every field of medicine relies on pathology — yet it remains analogue, slow, and reactive. • Surgeons operate partly blind, without real-time tissue assessment. • Repeat procedures and delayed results create more risk, overload hospitals, delay treat
Slide 10: From bottleneck to breakthrough
From bottleneck to breakthrough Imagine pathology that’s real-time, digital, and at the point of care! Imagine doctors diagnosing conditions on the spot without biopsies or delays! Imagine surgeons treating cancers completely first time, every time! Imagine pathologists seeing cells live during the
Slide 11: One technology, many markets
One technology, many markets • Medical: real-time surgery, digital pathology, robotic integration. • Veterinary: oncology, minimally invasive procedures, point of care. • Telepathology and AI/ML: remote consultation, digital workflows, decision support. • Life sciences: live, longitudinal imaging, r
Slide 12: The next era of medicine
The next era of medicine Clinical Device Family Vision + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecular Surgery Horizontall
Slide 13: FY25
FY25
Slide 14: FY25 – A year of convergence
FY25 – A year of convergence FY25 marked a pivotal point in Optiscan’s journey — the year our technology, partnerships, and clinical programs came together to advance from development to validation. Why it matters Every milestone achieved this year was part of a deliberate strategy to strengthen reg
Slide 15: Building the bridge to submission
Building the bridge to submission A Year of Strategic Progress FY25 marked a pivotal year in Optiscan’s transformation as the company moved from development to clinical validation and laying the operational, technical, and regulatory foundations required for future regulatory submissions. Clinical M
Slide 16: Significant milestones FY25
Significant milestones FY25 Key Achievements FY25 Clinical Optiscan Receives Ethical Clearance for Breast Cancer Study July 2024 Ethical clearance received from the Royal Melbourne Hospital Human Research Ethics Committee to undertake an in vivo clinical study for assessment of cancer margins in pat
Slide 17: Significant milestones FY25
Significant milestones FY25 Key Achievements FY25 Product InForm Imaging Device Revealed for Pathology February 2025 Reveal of Optiscan’s digital pathology device, expanding the Company’s clinical portfolio. Corporate Announce new CFO and Executive Appointments March 2025 Strengthened leadership tea
Slide 18: Advancing Digital Pathology Locally
Advancing Digital Pathology Locally
Slide 19: Advancing Digital Pathology Globally
Advancing Digital Pathology Globally
Slide 20: Financials
Financials
Slide 21: Secure financial footing
Secure financial footing Revenue and Other Income Cash on Hand R&D Expense (LHS) New Devices Revealed (RHS) Revenue Other Income $M $M $M 20 6 2 5 4 15 4 3 1 10 2 2 5 1 - - - - FY23 FY24 FY25 FY23 FY24 FY25 FY24 FY25 Sep25 (unaudited) R&D Expense & New Devices Revealed 3 new devices revealed over la
Slide 22: Key financial information
Key financial information Shareholders FY2025 Financial Information Revenue $0.95m EBITDA ($5.84m) Total Assets $10.55m 25.5% Total Liabilities $2.84m 37% 18.8% As of 30 Sep 2025 18.7% Cash $19.99m* Top 20 shareholders: 74.5% Capital raised $17.75m *Unaudited Peters Investments Pty Ltd Orchid Capita
Slide 23: Growth in Motion
Growth in Motion
Slide 24: From invention to commercialisation
From invention to commercialisation ➢ Optiscan is on a transformation journey; from OEM to pure play digital solutions provider. ➢ Optiscan now sits at a significant juncture; crossing from product development to commercial adoption. Phase 1: Phase 2: Phase 3: Core foundation Strategic transformatio
Slide 25: Devices with impact
Devices with impact ViewnVivo® InSpecta InVivage® InVue® InForm (Life sciences) (Veterinary) (Oral) (Surgery) (Pathology) Clinical Testing & Regulatory Submissions Underway
Slide 26: Product pipeline
Product pipeline Application Stage Collaborators Veterinary IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH 2026 MONITORING CLINICAL REGULATORY LAUNCH Surgical IDEATION PROTOTYPING PRECLINICAL 2025-2026 2026 2027 MONITORING Hardware Pathology IDEATION PROTOTYPING PRECLINIC
Slide 27: Commercialisation growth stages
Commercialisation growth stages 2028+ Market opportunity 2027 a) Surgery-Robotics: $3.92B b) Oral Imaging: $1.9B Market opportunity 2026 a) Surgery-Open(Breast and c) GI: $185B Head & Neck): $30B Market opportunity b) Pathology: $35.1B Notes: 2025 Veterinary market: $46.51B Notes: • Robotics market
Slide 28: Market Opportunities
Market Opprtunities
Slide 29: Growth opportunities
Growth opportunities >$100B market opportunity Veterinary Surgery Pathology InSpecta InVue® InForm
Slide 30: Veterinary market
Veterinary market InSpecta ASPECT P A S T ( P R E - 2 01 5 ) P R E S E NT & F U T U R E ( 2 0 2 5 + ) Care Model Reactive, walk-in Hybrid, proactive, digital-first Technology Use Minimal AI, wearables, telehealth, 3D printing Revenue Model Fee-for-service Subscription, wellness plans Telemedicine Ra
Slide 31: Surgery market
Surgery market InVue® MODERN – MINIMALLY INVASIVE & METRIC T R A D I TI O N A L - O P E N S U R GE RY R O B O TI C Incision Size Large Small (laparoscopic) or micro (robotic) Recovery Time Longer (weeks) Shorter (days to a week) Hospital Stay 5–10 days 1–3 days (robotic often <2 days) Complication R
Slide 32: Pathology market
Pathology market InForm METRIC T R A D I TI O N A L P A T H O L O GY DIGITAL PATHOLOGY Turnaround Time Slow due to manual handling Up to 50% faster with digital & AI Cost Low upfront, high operational High initial, long-term savings Market Opportunity (US) Mature market USD $1.5B (2024) → USD $4.5B
Slide 33: Gastrointestinal (GI) market
Gastrointestinal (GI) market GI Flexible Device METRIC T R A D I TI O N A L G I P R A C TI C E S M O D E R N G I P R A C T I C ES Manual endoscopy, X-rays, barium AI-assisted colonoscopy, capsule endoscopy, Technology studies molecular imaging General treatment protocols, symptom- Personalized medic
Slide 34: FY26 and Beyond
FY26 and Beyond
Slide 35: Positioned for growth
Positioned for growth Building on Momentum • FY25 marked a pivotal year as Optiscan transitioned from development to clinical validation. • FY26 will see this momentum accelerate, with a focus on commercial readiness and global expansion across veterinary and clinical markets. Clinical Advancement •
Slide 36: A category-defining opportunity
A category-defining opportunity This is the leap from analogue to digital, from delay to immediacy - and Optiscan is making it possible. • Revolutionary technology - the only platform delivering high resolution, real-time, sub-cellular, live microscopic imaging. • Multi-market growth – veterinary, p
Slide 37: Imaging in action
Imaging In action Optiscan”
Slide 38: Questions
Questions
Slide 39: Thank you for your attendance
THANK YOU FOR YOUR ATTENDANCE
Slide 40: Optiscan
Optiscan”
Optiscan Imaging — Shareholder Meeting (November 2025) on 6ix